Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: Adherence, fracture rates, and all-cause cost

Journal of Managed Care Pharmacy

Volumn 17, Issue 8, 2011, Pages 596-609

  Martin, Karen E ^a   Yu, Jingbo ^b   Campbell, H Eloise ^a   Abarca, Jacob ^a   White, T Jeffrey ^a  

^a Wellpoint Inc   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; FRACTURE REDUCTION; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PHARMACY; RISK FACTOR; SURVIVAL RATE;

EID: 84863021772     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.8.596     Document Type: Article

References (26)

1. National Osteoporosis Foundation. Fast facts. Available at: www.nof.org/node/40. Accessed September 6, 2011.
2. National Osteoporosis Foundation. NOF clinician's guide to prevention and treatment of osteoporosis. 2010. Available at: http://www.nof.org/professionals/clinical-guidelines. Accessed September 6, 2011.
3. Management of osteoporosis in postmenopausal women. 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1):25-54.
4. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16(Suppl 3):S1-S37.
5. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int. 2005;16(5):468-74.
6. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-41.
7. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077-82. Available at: http://jama.ama-assn.org/content/280/24/2077.long. Accessed September 6, 2011.
8. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344-52. Available at: http://jama.ama-assn.org/content/282/14/1344.long. Accessed September 6, 2011.
9. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241-49.
10. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int. 2007;18(1):25-34. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1705543/pdf/198_2006_Article_274.pdf. Accessed September 6, 2011.
11. Harris ST, Reginster JY, Harley C, et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone. 2009;44(5):758-65.
12. Watts NB, Worley K, Solis A, Doyle J, Sheer R. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm. 2004;10(2):142-51. Available at: http://www.amcp.org/data/jmcp/Formulary%20Management-142-151.pdf.
13. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-22. Available at: http://www.mayoclinicproceedings.com/content/81/8/1013.full.pdf+html. Accessed September 6, 2011.
14. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38(6):922-28.
15. Desai SS, Duncan BS, Sloan AS. The cost of treating osteoporosis in a managed health care organization. J Manag Care Pharm. 2003;9(2):142-49. Available at: http://www.amcp.org/data/jmcp/Research-142-149.pdf.
16. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, allcause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011;17(1):25-39. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8963.
17. Sun P, Zhao Y, Ray S. How to improve the quality of medication adherence estimates derived from healthcare claims or electronic medical records databases. Presented at: The 14th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR); May 16-20, 2009; Orlando, FL.
18. Zhao Y, Sun P, Watson P. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin. Curr Med Res Opin. 2011;27(4):785-92.
19. Zhao Y, Sun P, Watson P, Mitchell B, Swindle R. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract. 2011;11(3):204-16.
20. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;1(1)1:44-47.
21. LaFleur J, Oderda GM. Methods to measure patient compliance with medication regimens. J Pain Palliat Care Pharmacother. 2004;18(3):81-87.
22. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12.
23. Warriner AH, Patkar NM, Curtis JR, et al. Which fractures are most attributable to osteoporosis? J Clin Epidemiol. 2011;64(1):46-53.
24. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-19.
25. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7-8):1280-88.
26. Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int. 2011;22(3):741-53.